Wall Street Zen upgraded shares of Celularity (NASDAQ:CELU – Free Report) to a hold rating in a research note released on Saturday,Wall Street Zen reports.
Separately, Weiss Ratings upgraded Celularity from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 27th. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the company has an average rating of “Sell”.
View Our Latest Stock Analysis on CELU
Celularity Stock Down 1.7%
Celularity (NASDAQ:CELU – Get Free Report) last announced its quarterly earnings data on Tuesday, October 20th. The company reported $0.02 EPS for the quarter. The business had revenue of $5.43 million during the quarter.
Hedge Funds Weigh In On Celularity
A hedge fund recently bought a new stake in Celularity stock. C V Starr & Co. Inc. purchased a new position in shares of Celularity, Inc. (NASDAQ:CELU – Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 764,069 shares of the company’s stock, valued at approximately $1,582,000. Celularity accounts for about 0.8% of C V Starr & Co. Inc.’s investment portfolio, making the stock its 4th largest position. C V Starr & Co. Inc. owned approximately 2.64% of Celularity at the end of the most recent reporting period. Hedge funds and other institutional investors own 19.02% of the company’s stock.
About Celularity
Celularity is a biotechnology company that develops cell therapies and other products derived from the human placenta. Its platform uses cells collected after childbirth, which the company processes for potential use in regenerative medicine and treatment of disease. The company’s research includes placental-derived natural killer cells and other cell types being developed for potential applications in cancer and other conditions. Its pipeline has included candidates such as CYNK-001, an investigational natural killer cell therapy.
See Also
- Five stocks we like better than Celularity
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Celularity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celularity and related companies with MarketBeat.com's FREE daily email newsletter.
